O'Connor G T, Malenka D J, Olmstead E M, Johnson P S, Hennekens C H
Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire.
Am J Prev Med. 1992 May-Jun;8(3):186-92.
The efficacy of fish oil in decreasing restenosis following percutaneous transluminal coronary angioplasty (PTCA) remains controversial despite seven published reports of randomized trials involving 951 patients. We performed a meta-analysis to determine whether these trials, viewed in aggregate, demonstrate a significant benefit. We evaluated rates of restenosis two to 12 months after PTCA and calculated an estimate of the overall effect and 95% confidence interval (CI). The typical odds ratio (treatment versus control) was 0.71 (95% CI 0.54, 0.94), P = 0.016 (two-tailed). The data show a strong and highly significant (P less than .0001) relationship between daily fish oil dose and gastrointestinal side effects. While compatible with a small to moderate benefit of fish oil on rates of restenosis, these results require confirmation in a randomized clinical trial large enough to distinguish reliably between a clinically meaningful benefit and a null result.
尽管已有7篇关于涉及951例患者的随机试验的发表报告，但鱼油在经皮腔内冠状动脉成形术（PTCA）后降低再狭窄方面的疗效仍存在争议。我们进行了一项荟萃分析，以确定这些试验综合来看是否显示出显著益处。我们评估了PTCA术后2至12个月的再狭窄率，并计算了总体效应估计值和95%置信区间（CI）。典型的比值比（治疗组与对照组）为0.71（95%CI 0.54，0.94），P = 0.016（双侧）。数据显示每日鱼油剂量与胃肠道副作用之间存在强烈且高度显著（P小于0.0001）的关系。虽然与鱼油对再狭窄率有小到中度益处相符，但这些结果需要在足够大的随机临床试验中得到证实，以可靠地区分具有临床意义的益处和无效果的结果。
